Merus N.V.: Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD ...
This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length mult ...